A multi-center, open-label extension study to examine the safety and tolerability of ACP-103 in the treatment of psychosis in Parkinson's disease
Latest Information Update: 08 Mar 2024
At a glance
- Drugs Pimavanserin (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Acadia Pharmaceuticals
- 03 Jun 2021 Results published in the Acadia Pharmaceuticals Media Release
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
- 08 Jun 2018 Status changed from active, no longer recruiting to completed.